NDC Pharma SA
3.2 FTEThe score of NDC Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1 % Total assets +38 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
NDC Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 188,352 € | ||||
| Equity | 234,089 € | ||||
| Cash | 105,151 € | ||||
| EBITDA | 215,668 € | ||||
| Total assets | 772,892 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 29 Dec 2025
- Year ended 30 Jun 2024filed on 10 Jan 2025
- Year ended 30 Jun 2023filed on 19 Jan 2024
- Year ended 30 Jun 2022filed on 31 Jan 2023
- Year ended 30 Jun 2021filed on 17 Jan 2022
NDC Pharma's financial analysis
- Solvency30.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of NDC Pharma
NDC Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0429.465.124
- VAT number
- BE0429465124
- Peppol
- Registered · 0208:0429465124 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 26 Sep 1986
- Registered office
- 8830 Hooglede
- Size
- Micro · 3.2 FTE
- Latest accounts
- 2025 · filed on 29 Dec 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
NDC Pharma (SA) has been based in Hooglede since 1986, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 188,352 € and equity of 234,089 €; its revenue is not published. With 3.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 30.3%, below the median of its sector (44.2%).
Companies similar to NDC Pharma
Companies in the same business, of comparable size and area, outside its group.
- Frapeja Pharma Retail sale of pharmaceutical products Ghent · balance sheet 772,946 €
- Pharmacie Blairvacq Retail sale of pharmaceutical products Waremme · balance sheet 773,237 €
- Pharmacies GOFFIN Retail sale of pharmaceutical products Liège · balance sheet 771,286 €
- Brehophar Retail sale of pharmaceutical products Oostkamp · balance sheet 775,082 €
- CBKX Pharma Retail sale of pharmaceutical products Ghent · balance sheet 775,561 €
- Apotheek Kastel Retail sale of pharmaceutical products Kasterlee · balance sheet 770,049 €
- D’hONDT FARMA Retail sale of pharmaceutical products Hamme (Vl.) · balance sheet 776,363 €
- Deraphar Retail sale of pharmaceutical products Zelzate · balance sheet 778,926 €
Frequently asked questions about NDC Pharma
What is the revenue of NDC Pharma?
NDC Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of NDC Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0429465124 for NDC Pharma, if the company is VAT-registered. Its company number (CBE) is 0429.465.124.
Where is the registered office of NDC Pharma?
According to the CBE register, the registered office of NDC Pharma is in 8830 Hooglede.
What is the equity of NDC Pharma?
At the close of the 2025 financial year, the equity of NDC Pharma amounts to 234,089 €, a solvency of 30.3% of total assets.
How many people work at NDC Pharma?
3.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages NDC Pharma?
The register lists 2 active mandates at NDC Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of NDC Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →